Results 241 to 250 of about 1,152,447 (302)

COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. [PDF]

Healthcare (Basel)
Puigdellívol-Sánchez A, Juanes-González M, Calderón-Valdiviezo AI, Losa-Puig H, González-Salvador M, León-Pérez M, Pueyo-Antón L, Franco-Romero M, Lozano-Paz C, Cortés-Borra A, Valls-Foix R.   +10 more
europepmc   +1 more source

Flavonoid carbamate hybrids: design, synthesis, and evaluation as multi-target enzyme inhibitors for Alzheimer's disease. [PDF]

RSC Adv
Tran TH, Doan DN, Cao TC, Tran TS, Tran TD.   +4 more
europepmc   +1 more source

Comparative Risk Assessment in Hypertensive Patients With Metabolic Syndrome by Exploring Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. [PDF]

Cureus
Khan MH, Pathan S, Ansari K, Baig S, Ghafoor A, Minhas M, Saleem K.   +6 more
europepmc   +1 more source

Reducing the Risk of Developing Diabetes: The Role of Angiotensin Receptor Blockers and Angiotensin Converting Enzyme Inhibitors in Patients With Hypertension Combined Prediabetes. [PDF]

J Clin Hypertens (Greenwich)
Yang C, Hu Z, Sa R, Li R, Li Y, Wu Y, Shi G, Qiu L, Li C.   +8 more
europepmc   +1 more source

<i>Origanum vulgare</i> subsp. <i>virens</i> (Hoffmanns. & Link) Bonnier & Layens Essential Oils: Chemotypes and Bioactivity as Antifungal, Antifeeding and Enzyme Inhibitors. [PDF]

Plants (Basel)
Ferreira R, Martins M, Santos V, Sardinha D, Tavares WR, Sabina S, Espinel G, Barreto MC, Oliveira L, Cabrera R, Castilho P.   +10 more
europepmc   +1 more source

Epigenetic drug screening identifies enzyme inhibitors A-196 and TMP-269 as novel regulators of sprouting angiogenesis. [PDF]

Sci Rep
Beter M, Pulkkinen HH, Örd T, Sormunen A, Kilpeläinen L, Dunford JE, Kaikkonen MU, Aavik E, Laham-Karam N, Oppermann U, Laakkonen JP, Ylä-Herttuala S.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

[Angiotensin-converting enzyme inhibitors].

Recenti progressi in medicina, 1991
The introduction of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension and heart failure is probably the most important advance in cardiovascular pharmacotherapy in the last few decades. Although the role of the renin-angiotensin system (RAS) in cardiovascular diseases had been investigated extensively for more than 70 yr,
Irene Gavras, Haralambos Gavras
openaire   +4 more sources

Angiotensin-converting enzyme inhibitors

Critical Care Nurse, 1990
This review focuses on the use of angiotensin converting enzyme (ACE) inhibitors in hypertensive diseases. Specifically discussed are: proposed mechanisms of action, the pharmacology of the commercially available ACE inhibitors (captopril, enalapril, and lisinopril), their renal effects, and their safety and efficacy.
B L, Herlihy, J T, Herlihy
openaire   +4 more sources

Inhibitors of glyoxalase enzymes

Biochemical and Biophysical Research Communications, 1980
Abstract Both glyoxalase enzymes from various sources are inhibited by nucleotides, nucleosides and a series of structurally related compounds in an apparently cooperative manner. In general, aromatic compounds, which contain heterocyclic nitrogen and/or have amino groups on the aromatic ring, are effective inhibitors of these enzymes.
B, Oray, S J, Norton
openaire   +2 more sources